Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months

Phase 4

• Conditions: Hand Foot and Mouth Disease
• Interventions: Biological: the second batch vaccine; Biological: the first batch vaccine; Biological: the third batch vaccine

• Registration Number: NCT02889497
• Lead Sponsor: Beijing Chaoyang District Centre for Disease Control and Prevention

Brief Summary

This study evaluates the safety,three batches consistency and immunity duration of the post-marketing inactivated Enterovirus Type 71 (EV71) vaccine in children aged 6-71 months.This study has two groups:safety observation group and immunogenicity observation group.20000 subjects will receive 2 doses vaccines and be observed for safety among 2 epidemic cycles of HFMD.In the immunogenicity observation group, 900 subjects will be randomly received 3 batches vaccines(2 doses),and blood sampled at days 0 and 56.

Detailed Description

Not available

Study Timeline

• Status Verified: 2016-08
• Study First Submitted: 2016-08-31
• Study Start: 2016-09
• Study First Submitted QC: 2016-09-02
• Study First Posted: 2016-09-05
• Last Update Submitted: 2016-09-06
• Last Update Posted: 2016-09-07
• Primary Completion: 2019-03
• Study Completion: 2019-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20900

Inclusion Criteria

• 8 Months to 71 Months (Healthy Children or Infants)；
• Providing the subjects' legal identity certificate (birth certificate , residence booklet or ID card) and vaccination certificate, legal guardians can provide legal identity proof (resident booklet or ID card) so that the doctor can determine the subject identity to complete recruitment program；
• The subjects' guardians are able to understand and sign the informed consent voluntary. Guardians have the ability to use the thermometer ,dividing ruler and can fill out the Diary card ,follow-up card according to requirements；
• Persist for a 24 months visit.If doubtful HFMD case happen，the subject's guardian should send the subject to the medical institutions at above the county level and report this case to the investigator.The subjects who participate immunogenicity observation group can receive sample collection including blood，throat swab or anal awab according to program requirements.

Exclusion Criteria

• Exclusion Criteria for the first dose:

  • Subject with clinical diagnosis or suspect HFMD（Especially the history of herpangina）；
  • Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine；
  • History of seizures,convulsions or twitching ;Family history of progressive neurological disease；
  • Autoimmune disease or immunologic deficiency.Any prior administration of immunodepressant in last 6month；
  • History of asthma，thyroid ablation，angioneurotic edema, diabetes mellitus or malignant tumour；
  • Alienia，functional asplenia，or any condition that cause asplenia or splenectomy；
  • Diagnosed coagulation abnormalities (such as clotting factor deficiency, coagulation disorders, platelet disorder) or significant bruising or blood clotting disorder；
  • Any acute disease or chronic disease attack in last 7 days；
  • Any prior administration of blood products in last 3 month；
  • Any prior administration of attenuated live vaccine in last 15 days , subunit or inactivated vaccines in last 7 days；
  • Fever before vaccination, axillary temperature ﹥37.0℃；
  • Attend Other vaccine or drug clinical trials concurrent in 6 months；
  • Any condition that in the opinion of the investigator。

• Exclusion Criteria for the second dose:

  • Any exclusion criteria for the first dose happens after been enrolled；
  • Newly HFMD diagnosed patients after been enrolled；
  • Any condition that in the opinion of the investigator or ethics committee think should be eliminated.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
300 subjects receive the second batch vaccine	the second batch vaccine	300 subjects will be randomly received the second batch vaccine
300 subjects receive the first batch vaccine	the first batch vaccine	300 subjects will be randomly received the first batch vaccine
300 subjects receive the third batch vaccine	the third batch vaccine	300 subjects will be randomly received the third batch vaccine

Primary Outcome Measures

Name	Time	Method
Evaluate the Rate of Adverse reactions of Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months.	24 months	Adverse reactions associated with vaccine will be observed in Children Aged 6-71 Months after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy.
Evaluate the seroconversion rate of EV71 antibodies in serum after vaccination.	56 days	The seroconversion rate of EV71 antibodies will be evaluated in serum at days 0 and 56.